Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
92.99 USD +0.55% Intraday chart for BioNTech SE -3.44% -11.89%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Dpa-AFX Overview: COMPANIES from 14.03.2024 - 15:15 DP
Syncona portfolio company Autolus posts widened loss for 2023 AN
Dermapharm looks cautiously into the future - missing Covid business DP
BioNTech to Present Clinical Data Updates on Cancer Vaccine Candidates MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
BioNTech Says Chief Business and Commercial Officer Sean Marett to Retire MT
BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer CI
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
BMO Capital Initiates Coverage on BioNTech With Outperform Rating, $127 Price Target MT
Canaccord Genuity Adjusts Price Target on BioNTech to $171 From $168, Maintains Buy Rating MT
Dpa-AFX Overview: COMPANIES from 14.02.2024 - 15:15 DP
Putin says Russia is close to creating cancer vaccines RE
UK Regulator Approves Pfizer–BioNTech’s COVID-19 Vaccine License Change MT
BioNTech, Autolus to Advance CAR-T Cell Therapy Programs; Autolus Prices $350 Million Offering MT
BioNTech Signs License, Investment Deals With Autolus Therapeutics MT
BioNTech Agrees To Invest $200 Million in Autolus, Starts Strategic Collaboration DJ
BioNTech SE and Autolus Therapeutics plc Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs CI
Autolus Therapeutics plc announced that it expects to receive $220.000002 million in funding from BioNTech SE CI
Study: Germany leads Europe in patent applications against cancer DP
BioNTech, Duality Biologics Obtain FDA Fast Track Designation for Ovarian Cancer Therapy Candidate MT
BioNTech SE and Duality Biologics Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305 CI
BioNTech's Cancer Therapy Candidate Obtains Fast-track Designation from US FDA MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6% MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Thursday Trading MT
HC Wainwright Adjusts BioNTech Price Target to $107 From $133, Maintains Buy Rating MT
Chart BioNTech SE
More charts
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
85.53 EUR
Average target price
116.4 EUR
Spread / Average Target
+36.08%
Consensus
  1. Stock
  2. Equities
  3. Stock BioNTech SE - Nasdaq
  4. News BioNTech SE
  5. BioNTech : European ADRs Down 2.3% as Stock Markets Slump Monday